{
  "file_name": "CUAD_v1/full_contract_pdf/Part_I/License_Agreements/CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement.pdf",
  "annotations": [
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "COMMERCIALIZATION AND LICENSE AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Vyera",
      "page_number": 0,
      "words": [
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Vyera Pharmaceuticals, LLC",
      "page_number": 0,
      "words": [
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CytoDyn Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CytoDyn and Vyera are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties.\"",
      "page_number": 0,
      "words": [
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "CytoDyn",
      "page_number": 0,
      "words": [
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "December 17, 2019",
      "page_number": 0,
      "words": [
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "December 17, 2019",
      "page_number": 0,
      "words": [
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Expiration Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement (\"Term\") shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall expire on the last day of the Royalty Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Governing Law_0",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to any choice of law principles that would result in the application of the laws of any other jurisdiction.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Non-Compete_0",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "(c) Vyera breaches its obligations or covenants under Section 2.6 (Competitive Products);",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Non-Compete_0",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "CytoDyn shall have the right to terminate this Agreement in its entirety upon written notice to Vyera on the occurrence of any of the following:",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Non-Compete_0",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Except as expressly required under this Agreement, Vyera hereby covenants not to Develop, Manufacture, Commercialize or otherwise exploit a Competitive Product in the Territory during the Royalty Term, including by means of an Affiliate.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Exclusivity_0",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Vyera shall purchase all of its requirements for supply of Licensed Product exclusively from CytoDyn in accordance with the terms and conditions of the Supply Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Exclusivity_0",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "CytoDyn hereby grants to Vyera, and Vyera hereby accepts, an exclusive royalty-bearing license (or sublicense, as the case may be), under the CytoDyn Patents, the CytoDyn Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Exclusivity_2",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Without limiting the foregoing, Vyera shall have the exclusive right and responsibility throughout the Territory for the following: (a) receiving and accepting orders for the Licensed Product from customers; (b) distributing the Licensed Product to customers; (c) controlling invoicing and collection of accounts receivable for Licensed Product sales; (d) recording Licensed Product sales in its books of account for sales (in accordance with Vyera's accounting standards consistently applied (currently GAAP)); (e) subject to Section 5.5, determining pricing for the Licensed Product and all aspects of the promotion (including promotional materials) to be used in Commercializing Licensed Products; (f) negotiating with Third Parties, including without limitation, payors, pharmacy benefit managers and distributors, with respect to sales and distribution of Licensed Product; and (g) paying all rebates, chargebacks and other amounts due to customers in respect of Licensed Products (it being understood that all such amounts shall be deducted in calculating Net Sales).",
      "page_number": 2,
      "words": [
        {
          "text": "1.20 \"Claim\" has the meaning set forth in Section 13.1..",
          "bbox": [
            277.0,
            292.0,
            1271.0,
            333.0
          ],
          "confidence": 0.9812736511230469
        },
        {
          "text": "1.21 \"Clinical Trial' means any human clinical study or trial of a Licensed Product in the Field in the Territory..",
          "bbox": [
            275.0,
            398.0,
            2275.0,
            446.0
          ],
          "confidence": 0.987525463104248
        },
        {
          "text": "1.22 \"Combination Product\"' means a product that is Commercialized by Vyera and/or its Affiliates under this Agreement and that comprises, consists of,",
          "bbox": [
            275.0,
            510.0,
            3040.0,
            554.0
          ],
          "confidence": 0.9895656108856201
        },
        {
          "text": "or incorporates two or more APIs (whether administered together or separately), which includes leronlimab as one of the APIs together with one or more",
          "bbox": [
            277.0,
            566.0,
            3030.0,
            610.0
          ],
          "confidence": 0.9959484934806824
        },
        {
          "text": "additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the formulation or mode of administration of such",
          "bbox": [
            276.0,
            621.0,
            2929.0,
            663.0
          ],
          "confidence": 0.9954297542572021
        },
        {
          "text": "Combination Product. For the sake of clarity, a Combination Product is a Licensed Product.",
          "bbox": [
            279.0,
            678.0,
            1912.0,
            714.0
          ],
          "confidence": 0.9996550679206848
        },
        {
          "text": "1.23 \"Commercial Failure' means that Vyera fails to achieve aggregate [***].",
          "bbox": [
            274.0,
            778.0,
            1691.0,
            830.0
          ],
          "confidence": 0.9877095222473145
        },
        {
          "text": "1.24 \"Commercialization' means any and all pre-launch, launch and post-launch activities related to the marketing, promoting, distributing (to Third",
          "bbox": [
            279.0,
            894.0,
            2971.0,
            936.0
          ],
          "confidence": 0.9911439418792725
        },
        {
          "text": "Parties), offering for sale and selling a Licensed Product in the Field in the Territory. For clarity, Commercialization does not include Development and/or",
          "bbox": [
            277.0,
            948.0,
            3016.0,
            990.0
          ],
          "confidence": 0.9954667687416077
        },
        {
          "text": "Manufacturing of a Licensed Product. When used as a verb, \"Commercialize\" means to engage in Commercialization..",
          "bbox": [
            277.0,
            1003.0,
            2411.0,
            1045.0
          ],
          "confidence": 0.9929887652397156
        },
        {
          "text": "1.25 \"Commercialization Plan\"' has the meaning set forth in Section 5.2.",
          "bbox": [
            277.0,
            1109.0,
            1584.0,
            1151.0
          ],
          "confidence": 0.9814334511756897
        },
        {
          "text": "1.26 \"Commercially Reasonable Efforts\"' means: (a) with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its",
          "bbox": [
            279.0,
            1222.0,
            2944.0,
            1259.0
          ],
          "confidence": 0.989510178565979
        },
        {
          "text": "Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective,",
          "bbox": [
            279.0,
            1274.0,
            2933.0,
            1316.0
          ],
          "confidence": 0.9922087788581848
        },
        {
          "text": "activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances; and (b) with",
          "bbox": [
            279.0,
            1332.0,
            2956.0,
            1369.0
          ],
          "confidence": 0.9923081398010254
        },
        {
          "text": "respect to Development and Commercialization of any Licensed Product for any indication by a Party, efforts and resources consistent with those efforts",
          "bbox": [
            274.0,
            1381.0,
            3036.0,
            1427.0
          ],
          "confidence": 0.9998706579208374
        },
        {
          "text": "and resources commonly used by a similarly situated biotechnology company with respect to a product owned by it or to which it has similar rights,",
          "bbox": [
            276.0,
            1438.0,
            2947.0,
            1480.0
          ],
          "confidence": 0.9859208464622498
        },
        {
          "text": "which product is at a similar stage in its development or product life and is of similar market potential taking into account (i) the patent and other",
          "bbox": [
            279.0,
            1493.0,
            2882.0,
            1535.0
          ],
          "confidence": 0.988565981388092
        },
        {
          "text": "proprietary position of the Licensed Product and (ii) the anticipated profitability of the Licensed Product..",
          "bbox": [
            277.0,
            1544.0,
            2171.0,
            1592.0
          ],
          "confidence": 0.9909676313400269
        },
        {
          "text": "1.27 \"Competitive Product' means any product for the treatment or prevention of [***], leronlimab that is not a Licensed Product..",
          "bbox": [
            277.0,
            1656.0,
            2628.0,
            1698.0
          ],
          "confidence": 0.9867275357246399
        },
        {
          "text": "1.28 \"Confidential Information\"' means, subject to Article 10, all non-public or proprietary information not otherwise included in Know-How disclosed by.",
          "bbox": [
            277.0,
            1765.0,
            3049.0,
            1807.0
          ],
          "confidence": 0.9923374652862549
        },
        {
          "text": "either Party to the other Party in connection with the activities contemplated by this Agreement, which may include ideas, inventions, discoveries,",
          "bbox": [
            277.0,
            1820.0,
            2918.0,
            1862.0
          ],
          "confidence": 0.9925811290740967
        },
        {
          "text": "concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,.",
          "bbox": [
            277.0,
            1877.0,
            2846.0,
            1913.0
          ],
          "confidence": 0.9897582530975342
        },
        {
          "text": "technology, inventories, machines, techniques, development, designs, drawings, computer programs, knowledge, skill, experience, documents, apparatus,",
          "bbox": [
            274.0,
            1926.0,
            3047.0,
            1974.0
          ],
          "confidence": 0.9925311803817749
        },
        {
          "text": "results, clinical and regulatory strategies, Regulatory Documentation, and submissions pertaining to, or made in association with, filings with any",
          "bbox": [
            274.0,
            1981.0,
            2902.0,
            2027.0
          ],
          "confidence": 0.9985519647598267
        },
        {
          "text": "Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and",
          "bbox": [
            279.0,
            2039.0,
            2949.0,
            2076.0
          ],
          "confidence": 0.9960005879402161
        },
        {
          "text": "descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product",
          "bbox": [
            279.0,
            2096.0,
            2991.0,
            2133.0
          ],
          "confidence": 0.9948955178260803
        },
        {
          "text": "samples and other samples, physical, chemical and biological materials and compounds and information related to such materials and compounds, and",
          "bbox": [
            277.0,
            2147.0,
            2991.0,
            2189.0
          ],
          "confidence": 0.9983083009719849
        },
        {
          "text": "any modifications, improvements, designs, and recipes without regard as to whether any of the foregoing is marked \"confidential' or \"proprietary,\" or",
          "bbox": [
            277.0,
            2202.0,
            2982.0,
            2246.0
          ],
          "confidence": 0.9895987510681152
        },
        {
          "text": "disclosed in oral, written, graphic, or electronic form. Confidential Information shall include the terms and conditions of this Agreement..",
          "bbox": [
            275.0,
            2253.0,
            2722.0,
            2299.0
          ],
          "confidence": 0.998028039932251
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9870999455451965
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Exclusivity_2",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "In the event that such assignment would be unlawful, Vyera shall, and hereby does, grant to CytoDyn an exclusive, irrevocable, worldwide, sublicensable (including through multiple tiers), transferrable (without consent) royalty free license to any and all right, title and/or interest that it may have in or to an Invention.",
      "page_number": 2,
      "words": [
        {
          "text": "1.20 \"Claim\" has the meaning set forth in Section 13.1..",
          "bbox": [
            277.0,
            292.0,
            1271.0,
            333.0
          ],
          "confidence": 0.9812736511230469
        },
        {
          "text": "1.21 \"Clinical Trial' means any human clinical study or trial of a Licensed Product in the Field in the Territory..",
          "bbox": [
            275.0,
            398.0,
            2275.0,
            446.0
          ],
          "confidence": 0.987525463104248
        },
        {
          "text": "1.22 \"Combination Product\"' means a product that is Commercialized by Vyera and/or its Affiliates under this Agreement and that comprises, consists of,",
          "bbox": [
            275.0,
            510.0,
            3040.0,
            554.0
          ],
          "confidence": 0.9895656108856201
        },
        {
          "text": "or incorporates two or more APIs (whether administered together or separately), which includes leronlimab as one of the APIs together with one or more",
          "bbox": [
            277.0,
            566.0,
            3030.0,
            610.0
          ],
          "confidence": 0.9959484934806824
        },
        {
          "text": "additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the formulation or mode of administration of such",
          "bbox": [
            276.0,
            621.0,
            2929.0,
            663.0
          ],
          "confidence": 0.9954297542572021
        },
        {
          "text": "Combination Product. For the sake of clarity, a Combination Product is a Licensed Product.",
          "bbox": [
            279.0,
            678.0,
            1912.0,
            714.0
          ],
          "confidence": 0.9996550679206848
        },
        {
          "text": "1.23 \"Commercial Failure' means that Vyera fails to achieve aggregate [***].",
          "bbox": [
            274.0,
            778.0,
            1691.0,
            830.0
          ],
          "confidence": 0.9877095222473145
        },
        {
          "text": "1.24 \"Commercialization' means any and all pre-launch, launch and post-launch activities related to the marketing, promoting, distributing (to Third",
          "bbox": [
            279.0,
            894.0,
            2971.0,
            936.0
          ],
          "confidence": 0.9911439418792725
        },
        {
          "text": "Parties), offering for sale and selling a Licensed Product in the Field in the Territory. For clarity, Commercialization does not include Development and/or",
          "bbox": [
            277.0,
            948.0,
            3016.0,
            990.0
          ],
          "confidence": 0.9954667687416077
        },
        {
          "text": "Manufacturing of a Licensed Product. When used as a verb, \"Commercialize\" means to engage in Commercialization..",
          "bbox": [
            277.0,
            1003.0,
            2411.0,
            1045.0
          ],
          "confidence": 0.9929887652397156
        },
        {
          "text": "1.25 \"Commercialization Plan\"' has the meaning set forth in Section 5.2.",
          "bbox": [
            277.0,
            1109.0,
            1584.0,
            1151.0
          ],
          "confidence": 0.9814334511756897
        },
        {
          "text": "1.26 \"Commercially Reasonable Efforts\"' means: (a) with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its",
          "bbox": [
            279.0,
            1222.0,
            2944.0,
            1259.0
          ],
          "confidence": 0.989510178565979
        },
        {
          "text": "Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective,",
          "bbox": [
            279.0,
            1274.0,
            2933.0,
            1316.0
          ],
          "confidence": 0.9922087788581848
        },
        {
          "text": "activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances; and (b) with",
          "bbox": [
            279.0,
            1332.0,
            2956.0,
            1369.0
          ],
          "confidence": 0.9923081398010254
        },
        {
          "text": "respect to Development and Commercialization of any Licensed Product for any indication by a Party, efforts and resources consistent with those efforts",
          "bbox": [
            274.0,
            1381.0,
            3036.0,
            1427.0
          ],
          "confidence": 0.9998706579208374
        },
        {
          "text": "and resources commonly used by a similarly situated biotechnology company with respect to a product owned by it or to which it has similar rights,",
          "bbox": [
            276.0,
            1438.0,
            2947.0,
            1480.0
          ],
          "confidence": 0.9859208464622498
        },
        {
          "text": "which product is at a similar stage in its development or product life and is of similar market potential taking into account (i) the patent and other",
          "bbox": [
            279.0,
            1493.0,
            2882.0,
            1535.0
          ],
          "confidence": 0.988565981388092
        },
        {
          "text": "proprietary position of the Licensed Product and (ii) the anticipated profitability of the Licensed Product..",
          "bbox": [
            277.0,
            1544.0,
            2171.0,
            1592.0
          ],
          "confidence": 0.9909676313400269
        },
        {
          "text": "1.27 \"Competitive Product' means any product for the treatment or prevention of [***], leronlimab that is not a Licensed Product..",
          "bbox": [
            277.0,
            1656.0,
            2628.0,
            1698.0
          ],
          "confidence": 0.9867275357246399
        },
        {
          "text": "1.28 \"Confidential Information\"' means, subject to Article 10, all non-public or proprietary information not otherwise included in Know-How disclosed by.",
          "bbox": [
            277.0,
            1765.0,
            3049.0,
            1807.0
          ],
          "confidence": 0.9923374652862549
        },
        {
          "text": "either Party to the other Party in connection with the activities contemplated by this Agreement, which may include ideas, inventions, discoveries,",
          "bbox": [
            277.0,
            1820.0,
            2918.0,
            1862.0
          ],
          "confidence": 0.9925811290740967
        },
        {
          "text": "concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,.",
          "bbox": [
            277.0,
            1877.0,
            2846.0,
            1913.0
          ],
          "confidence": 0.9897582530975342
        },
        {
          "text": "technology, inventories, machines, techniques, development, designs, drawings, computer programs, knowledge, skill, experience, documents, apparatus,",
          "bbox": [
            274.0,
            1926.0,
            3047.0,
            1974.0
          ],
          "confidence": 0.9925311803817749
        },
        {
          "text": "results, clinical and regulatory strategies, Regulatory Documentation, and submissions pertaining to, or made in association with, filings with any",
          "bbox": [
            274.0,
            1981.0,
            2902.0,
            2027.0
          ],
          "confidence": 0.9985519647598267
        },
        {
          "text": "Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and",
          "bbox": [
            279.0,
            2039.0,
            2949.0,
            2076.0
          ],
          "confidence": 0.9960005879402161
        },
        {
          "text": "descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product",
          "bbox": [
            279.0,
            2096.0,
            2991.0,
            2133.0
          ],
          "confidence": 0.9948955178260803
        },
        {
          "text": "samples and other samples, physical, chemical and biological materials and compounds and information related to such materials and compounds, and",
          "bbox": [
            277.0,
            2147.0,
            2991.0,
            2189.0
          ],
          "confidence": 0.9983083009719849
        },
        {
          "text": "any modifications, improvements, designs, and recipes without regard as to whether any of the foregoing is marked \"confidential' or \"proprietary,\" or",
          "bbox": [
            277.0,
            2202.0,
            2982.0,
            2246.0
          ],
          "confidence": 0.9895987510681152
        },
        {
          "text": "disclosed in oral, written, graphic, or electronic form. Confidential Information shall include the terms and conditions of this Agreement..",
          "bbox": [
            275.0,
            2253.0,
            2722.0,
            2299.0
          ],
          "confidence": 0.998028039932251
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9870999455451965
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Termination For Convenience_0",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "(c) at any time following the second (2nd) anniversary of the First Commercial Sale of the Licensed Product, for any reason or no reason, upon one hundred eighty (180) days' written notice to CytoDyn.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Termination For Convenience_0",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Vyera shall have the right to terminate this Agreement in its entirety:",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "For clarity, nothing in this Agreement shall prohibit Vyera from undergoing any Change of Control, but if Vyera undergoes a Change of Control, it will be subject to Section 2.6.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "In the event that Vyera experiences a Change of Control with a Third Party that is actively engaged in the Development, Manufacture or Commercialization of a Competitive Product, then, Vyera shall either: (a) within ninety (90) days after the closing of such Change of Control, enter into a binding written agreement to sell, transfer, assign or divest all of Vyera's and/or its Affiliate's rights in and to such Competitive Product to a non-Affiliate Third Party and consummate such sale, transfer, assignment or divestiture of said rights not later than ninety (90) days following the date of the binding Agreement; or (b) within six (6) months after the closing of such Change of Control, terminate any and all Development, Manufacturing, Commercialization and/or other exploitation of such Competitive Product; or (c) terminate this Agreement in accordance with Section 11.2(c).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "A Change of Control shall be deemed an assignment for purposes of this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Anti-Assignment_1",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "CytoDyn may assign this Agreement and its rights and obligations hereunder, in whole but not in part, to any Third Party not in a materially worse (financially and otherwise) of performing CytoDyn's obligations hereunder without the prior written consent of Vyera (it being understood that any other assignment of this Agreement or any rights or obligations hereunder shall require the prior written consent of Vyera, not to be unreasonably withheld or delayed).",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Anti-Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Vyera may not assign this Agreement, or any rights or obligations hereunder without the prior written consent of CytoDyn, not to be unreasonably withheld or delayed provided that Vyera may assign this Agreement without CytoDyn's consent to an Affiliate or to a successor to substantially all of the business of Vyera to which this Agreement relates.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Anti-Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any assignment or attempted assignment by Vyera in violation of the terms of this Section 14.6 shall be null, void and of no legal effect.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Revenue/Profit Sharing_0",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Vyera shall pay to CytoDyn royalties equal to fifty percent (50%) of Net Sales of Licensed Products in the Territory during the Royalty Term; provided that, after the Step-Down Date, the royalty percentage will be reduced to [***] of Net Sales of Licensed Products in the Territory throughout the remaining period in the Royalty Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Minimum Commitment_1",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "(d) Upon [***] written notice, in the event Vyera fails to meet any of the Minimum Requirements and has not cured such failure, to the extent curable, within such notice period;",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Minimum Commitment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "CytoDyn shall have the right to terminate this Agreement in its entirety upon written notice to Vyera on the occurrence of any of the following:",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Minimum Commitment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Vyera shall conduct the Commercialization activities in accordance with the Commercialization Plan and in performing such activities will ensure that it meets or exceeds the Minimum Requirements.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Ip Ownership Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Vyera will, upon reasonable request of CytoDyn, and at CytoDyn's expense, execute or cause to be executed, any assignments, filings, applications or other documents that CytoDyn may require to evidence its rights in the Inventions.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Ip Ownership Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "If Vyera acquires any rights in the Trademarks, by operation of Applicable Law, or otherwise, such rights shall be deemed and are hereby irrevocably assigned to CytoDyn without further action by either Party.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Ip Ownership Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "CytoDyn will be the sole owner of all trade dress, logos, slogans, designs and copyrights specifically created by or on behalf of Vyera or used by Vyera on or in connection with the Licensed Products in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Ip Ownership Assignment_0",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "To the fullest extent permitted by law, Vyera shall, and hereby does, assign all of its right title and interest in and to any and all Inventions to CytoDyn",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__License Grant_0",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Vyera shall have the exclusive right to implement, and subject to Section 5.5, final decision-making authority with respect to, Commercialization of all Licensed Products in the Field and the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__License Grant_0",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "CytoDyn hereby grants to Vyera, and Vyera hereby accepts, an exclusive royalty-bearing license (or sublicense, as the case may be), under the CytoDyn Patents, the CytoDyn Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__License Grant_0",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Vyera shall not Commercialize nor shall it authorize the Commercialization of any Licensed Product outside of the Field or outside of the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__License Grant_2",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "In the event that such assignment would be unlawful, Vyera shall, and hereby does, grant to CytoDyn an exclusive, irrevocable, worldwide, sublicensable (including through multiple tiers), transferrable (without consent) royalty free license to any and all right, title and/or interest that it may have in or to an Invention.",
      "page_number": 2,
      "words": [
        {
          "text": "1.20 \"Claim\" has the meaning set forth in Section 13.1..",
          "bbox": [
            277.0,
            292.0,
            1271.0,
            333.0
          ],
          "confidence": 0.9812736511230469
        },
        {
          "text": "1.21 \"Clinical Trial' means any human clinical study or trial of a Licensed Product in the Field in the Territory..",
          "bbox": [
            275.0,
            398.0,
            2275.0,
            446.0
          ],
          "confidence": 0.987525463104248
        },
        {
          "text": "1.22 \"Combination Product\"' means a product that is Commercialized by Vyera and/or its Affiliates under this Agreement and that comprises, consists of,",
          "bbox": [
            275.0,
            510.0,
            3040.0,
            554.0
          ],
          "confidence": 0.9895656108856201
        },
        {
          "text": "or incorporates two or more APIs (whether administered together or separately), which includes leronlimab as one of the APIs together with one or more",
          "bbox": [
            277.0,
            566.0,
            3030.0,
            610.0
          ],
          "confidence": 0.9959484934806824
        },
        {
          "text": "additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the formulation or mode of administration of such",
          "bbox": [
            276.0,
            621.0,
            2929.0,
            663.0
          ],
          "confidence": 0.9954297542572021
        },
        {
          "text": "Combination Product. For the sake of clarity, a Combination Product is a Licensed Product.",
          "bbox": [
            279.0,
            678.0,
            1912.0,
            714.0
          ],
          "confidence": 0.9996550679206848
        },
        {
          "text": "1.23 \"Commercial Failure' means that Vyera fails to achieve aggregate [***].",
          "bbox": [
            274.0,
            778.0,
            1691.0,
            830.0
          ],
          "confidence": 0.9877095222473145
        },
        {
          "text": "1.24 \"Commercialization' means any and all pre-launch, launch and post-launch activities related to the marketing, promoting, distributing (to Third",
          "bbox": [
            279.0,
            894.0,
            2971.0,
            936.0
          ],
          "confidence": 0.9911439418792725
        },
        {
          "text": "Parties), offering for sale and selling a Licensed Product in the Field in the Territory. For clarity, Commercialization does not include Development and/or",
          "bbox": [
            277.0,
            948.0,
            3016.0,
            990.0
          ],
          "confidence": 0.9954667687416077
        },
        {
          "text": "Manufacturing of a Licensed Product. When used as a verb, \"Commercialize\" means to engage in Commercialization..",
          "bbox": [
            277.0,
            1003.0,
            2411.0,
            1045.0
          ],
          "confidence": 0.9929887652397156
        },
        {
          "text": "1.25 \"Commercialization Plan\"' has the meaning set forth in Section 5.2.",
          "bbox": [
            277.0,
            1109.0,
            1584.0,
            1151.0
          ],
          "confidence": 0.9814334511756897
        },
        {
          "text": "1.26 \"Commercially Reasonable Efforts\"' means: (a) with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its",
          "bbox": [
            279.0,
            1222.0,
            2944.0,
            1259.0
          ],
          "confidence": 0.989510178565979
        },
        {
          "text": "Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective,",
          "bbox": [
            279.0,
            1274.0,
            2933.0,
            1316.0
          ],
          "confidence": 0.9922087788581848
        },
        {
          "text": "activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances; and (b) with",
          "bbox": [
            279.0,
            1332.0,
            2956.0,
            1369.0
          ],
          "confidence": 0.9923081398010254
        },
        {
          "text": "respect to Development and Commercialization of any Licensed Product for any indication by a Party, efforts and resources consistent with those efforts",
          "bbox": [
            274.0,
            1381.0,
            3036.0,
            1427.0
          ],
          "confidence": 0.9998706579208374
        },
        {
          "text": "and resources commonly used by a similarly situated biotechnology company with respect to a product owned by it or to which it has similar rights,",
          "bbox": [
            276.0,
            1438.0,
            2947.0,
            1480.0
          ],
          "confidence": 0.9859208464622498
        },
        {
          "text": "which product is at a similar stage in its development or product life and is of similar market potential taking into account (i) the patent and other",
          "bbox": [
            279.0,
            1493.0,
            2882.0,
            1535.0
          ],
          "confidence": 0.988565981388092
        },
        {
          "text": "proprietary position of the Licensed Product and (ii) the anticipated profitability of the Licensed Product..",
          "bbox": [
            277.0,
            1544.0,
            2171.0,
            1592.0
          ],
          "confidence": 0.9909676313400269
        },
        {
          "text": "1.27 \"Competitive Product' means any product for the treatment or prevention of [***], leronlimab that is not a Licensed Product..",
          "bbox": [
            277.0,
            1656.0,
            2628.0,
            1698.0
          ],
          "confidence": 0.9867275357246399
        },
        {
          "text": "1.28 \"Confidential Information\"' means, subject to Article 10, all non-public or proprietary information not otherwise included in Know-How disclosed by.",
          "bbox": [
            277.0,
            1765.0,
            3049.0,
            1807.0
          ],
          "confidence": 0.9923374652862549
        },
        {
          "text": "either Party to the other Party in connection with the activities contemplated by this Agreement, which may include ideas, inventions, discoveries,",
          "bbox": [
            277.0,
            1820.0,
            2918.0,
            1862.0
          ],
          "confidence": 0.9925811290740967
        },
        {
          "text": "concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,.",
          "bbox": [
            277.0,
            1877.0,
            2846.0,
            1913.0
          ],
          "confidence": 0.9897582530975342
        },
        {
          "text": "technology, inventories, machines, techniques, development, designs, drawings, computer programs, knowledge, skill, experience, documents, apparatus,",
          "bbox": [
            274.0,
            1926.0,
            3047.0,
            1974.0
          ],
          "confidence": 0.9925311803817749
        },
        {
          "text": "results, clinical and regulatory strategies, Regulatory Documentation, and submissions pertaining to, or made in association with, filings with any",
          "bbox": [
            274.0,
            1981.0,
            2902.0,
            2027.0
          ],
          "confidence": 0.9985519647598267
        },
        {
          "text": "Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and",
          "bbox": [
            279.0,
            2039.0,
            2949.0,
            2076.0
          ],
          "confidence": 0.9960005879402161
        },
        {
          "text": "descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product",
          "bbox": [
            279.0,
            2096.0,
            2991.0,
            2133.0
          ],
          "confidence": 0.9948955178260803
        },
        {
          "text": "samples and other samples, physical, chemical and biological materials and compounds and information related to such materials and compounds, and",
          "bbox": [
            277.0,
            2147.0,
            2991.0,
            2189.0
          ],
          "confidence": 0.9983083009719849
        },
        {
          "text": "any modifications, improvements, designs, and recipes without regard as to whether any of the foregoing is marked \"confidential' or \"proprietary,\" or",
          "bbox": [
            277.0,
            2202.0,
            2982.0,
            2246.0
          ],
          "confidence": 0.9895987510681152
        },
        {
          "text": "disclosed in oral, written, graphic, or electronic form. Confidential Information shall include the terms and conditions of this Agreement..",
          "bbox": [
            275.0,
            2253.0,
            2722.0,
            2299.0
          ],
          "confidence": 0.998028039932251
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9870999455451965
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Non-Transferable License_1",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "The licenses granted to Vyera under this Agreement shall not be transferrable and/or sublicensable without CytoDyn's written consent, which it may grant, condition or withhold in its sole discretion.",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Irrevocable Or Perpetual License_0",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Following the expiration of the Royalty Term with respect to the Licensed Product, the licenses granted under Section 2.1 with respect to such Licensed Product in the Field and the Territory shall be non-exclusive, perpetual, irrevocable, fully-paid and royalty-free.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Irrevocable Or Perpetual License_0",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Upon the expiration of the Royalty Term, the license granted to Vyera under Section 2.1 of this Agreement shall become non-exclusive, fully-paid, royalty free, perpetual and irrevocable.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Irrevocable Or Perpetual License_2",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "In the event that such assignment would be unlawful, Vyera shall, and hereby does, grant to CytoDyn an exclusive, irrevocable, worldwide, sublicensable (including through multiple tiers), transferrable (without consent) royalty free license to any and all right, title and/or interest that it may have in or to an Invention.",
      "page_number": 2,
      "words": [
        {
          "text": "1.20 \"Claim\" has the meaning set forth in Section 13.1..",
          "bbox": [
            277.0,
            292.0,
            1271.0,
            333.0
          ],
          "confidence": 0.9812736511230469
        },
        {
          "text": "1.21 \"Clinical Trial' means any human clinical study or trial of a Licensed Product in the Field in the Territory..",
          "bbox": [
            275.0,
            398.0,
            2275.0,
            446.0
          ],
          "confidence": 0.987525463104248
        },
        {
          "text": "1.22 \"Combination Product\"' means a product that is Commercialized by Vyera and/or its Affiliates under this Agreement and that comprises, consists of,",
          "bbox": [
            275.0,
            510.0,
            3040.0,
            554.0
          ],
          "confidence": 0.9895656108856201
        },
        {
          "text": "or incorporates two or more APIs (whether administered together or separately), which includes leronlimab as one of the APIs together with one or more",
          "bbox": [
            277.0,
            566.0,
            3030.0,
            610.0
          ],
          "confidence": 0.9959484934806824
        },
        {
          "text": "additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the formulation or mode of administration of such",
          "bbox": [
            276.0,
            621.0,
            2929.0,
            663.0
          ],
          "confidence": 0.9954297542572021
        },
        {
          "text": "Combination Product. For the sake of clarity, a Combination Product is a Licensed Product.",
          "bbox": [
            279.0,
            678.0,
            1912.0,
            714.0
          ],
          "confidence": 0.9996550679206848
        },
        {
          "text": "1.23 \"Commercial Failure' means that Vyera fails to achieve aggregate [***].",
          "bbox": [
            274.0,
            778.0,
            1691.0,
            830.0
          ],
          "confidence": 0.9877095222473145
        },
        {
          "text": "1.24 \"Commercialization' means any and all pre-launch, launch and post-launch activities related to the marketing, promoting, distributing (to Third",
          "bbox": [
            279.0,
            894.0,
            2971.0,
            936.0
          ],
          "confidence": 0.9911439418792725
        },
        {
          "text": "Parties), offering for sale and selling a Licensed Product in the Field in the Territory. For clarity, Commercialization does not include Development and/or",
          "bbox": [
            277.0,
            948.0,
            3016.0,
            990.0
          ],
          "confidence": 0.9954667687416077
        },
        {
          "text": "Manufacturing of a Licensed Product. When used as a verb, \"Commercialize\" means to engage in Commercialization..",
          "bbox": [
            277.0,
            1003.0,
            2411.0,
            1045.0
          ],
          "confidence": 0.9929887652397156
        },
        {
          "text": "1.25 \"Commercialization Plan\"' has the meaning set forth in Section 5.2.",
          "bbox": [
            277.0,
            1109.0,
            1584.0,
            1151.0
          ],
          "confidence": 0.9814334511756897
        },
        {
          "text": "1.26 \"Commercially Reasonable Efforts\"' means: (a) with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its",
          "bbox": [
            279.0,
            1222.0,
            2944.0,
            1259.0
          ],
          "confidence": 0.989510178565979
        },
        {
          "text": "Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective,",
          "bbox": [
            279.0,
            1274.0,
            2933.0,
            1316.0
          ],
          "confidence": 0.9922087788581848
        },
        {
          "text": "activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances; and (b) with",
          "bbox": [
            279.0,
            1332.0,
            2956.0,
            1369.0
          ],
          "confidence": 0.9923081398010254
        },
        {
          "text": "respect to Development and Commercialization of any Licensed Product for any indication by a Party, efforts and resources consistent with those efforts",
          "bbox": [
            274.0,
            1381.0,
            3036.0,
            1427.0
          ],
          "confidence": 0.9998706579208374
        },
        {
          "text": "and resources commonly used by a similarly situated biotechnology company with respect to a product owned by it or to which it has similar rights,",
          "bbox": [
            276.0,
            1438.0,
            2947.0,
            1480.0
          ],
          "confidence": 0.9859208464622498
        },
        {
          "text": "which product is at a similar stage in its development or product life and is of similar market potential taking into account (i) the patent and other",
          "bbox": [
            279.0,
            1493.0,
            2882.0,
            1535.0
          ],
          "confidence": 0.988565981388092
        },
        {
          "text": "proprietary position of the Licensed Product and (ii) the anticipated profitability of the Licensed Product..",
          "bbox": [
            277.0,
            1544.0,
            2171.0,
            1592.0
          ],
          "confidence": 0.9909676313400269
        },
        {
          "text": "1.27 \"Competitive Product' means any product for the treatment or prevention of [***], leronlimab that is not a Licensed Product..",
          "bbox": [
            277.0,
            1656.0,
            2628.0,
            1698.0
          ],
          "confidence": 0.9867275357246399
        },
        {
          "text": "1.28 \"Confidential Information\"' means, subject to Article 10, all non-public or proprietary information not otherwise included in Know-How disclosed by.",
          "bbox": [
            277.0,
            1765.0,
            3049.0,
            1807.0
          ],
          "confidence": 0.9923374652862549
        },
        {
          "text": "either Party to the other Party in connection with the activities contemplated by this Agreement, which may include ideas, inventions, discoveries,",
          "bbox": [
            277.0,
            1820.0,
            2918.0,
            1862.0
          ],
          "confidence": 0.9925811290740967
        },
        {
          "text": "concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,.",
          "bbox": [
            277.0,
            1877.0,
            2846.0,
            1913.0
          ],
          "confidence": 0.9897582530975342
        },
        {
          "text": "technology, inventories, machines, techniques, development, designs, drawings, computer programs, knowledge, skill, experience, documents, apparatus,",
          "bbox": [
            274.0,
            1926.0,
            3047.0,
            1974.0
          ],
          "confidence": 0.9925311803817749
        },
        {
          "text": "results, clinical and regulatory strategies, Regulatory Documentation, and submissions pertaining to, or made in association with, filings with any",
          "bbox": [
            274.0,
            1981.0,
            2902.0,
            2027.0
          ],
          "confidence": 0.9985519647598267
        },
        {
          "text": "Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and",
          "bbox": [
            279.0,
            2039.0,
            2949.0,
            2076.0
          ],
          "confidence": 0.9960005879402161
        },
        {
          "text": "descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product",
          "bbox": [
            279.0,
            2096.0,
            2991.0,
            2133.0
          ],
          "confidence": 0.9948955178260803
        },
        {
          "text": "samples and other samples, physical, chemical and biological materials and compounds and information related to such materials and compounds, and",
          "bbox": [
            277.0,
            2147.0,
            2991.0,
            2189.0
          ],
          "confidence": 0.9983083009719849
        },
        {
          "text": "any modifications, improvements, designs, and recipes without regard as to whether any of the foregoing is marked \"confidential' or \"proprietary,\" or",
          "bbox": [
            277.0,
            2202.0,
            2982.0,
            2246.0
          ],
          "confidence": 0.9895987510681152
        },
        {
          "text": "disclosed in oral, written, graphic, or electronic form. Confidential Information shall include the terms and conditions of this Agreement..",
          "bbox": [
            275.0,
            2253.0,
            2722.0,
            2299.0
          ],
          "confidence": 0.998028039932251
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9870999455451965
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Post-Termination Services_0",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event of a termination by Vyera under Section 11.2, the following terms shall apply: (i) at CytoDyn's request, the Parties will negotiate in good faith a transition services agreement (the \"Transition Services Agreement\"), under which Vyera will provide certain Commercialization services to CytoDyn in connection with CytoDyn efforts to Commercialize the Licensed Product in the Field in the Territory; (ii) the services to be provided by Vyera pursuant to the Transition Services Agreement (the \"Transition Services\") will be negotiated in good faith taking into account (A) the activities undertaken by Vyera in connection with the Commercialization of Licensed Product during the Term and (B) Vyera's then-existing resources and capabilities (it being understood and agreed that Vyera shall not (x) be required to hire any new employees or enter into any new agreements with Third Parties in order to provide the Transition Services or (y) terminate any employee or agreement the primary purpose of which is to circumvent its obligations to provide the Transition Services); (iii) the Transition Services Agreement will require Vyera to provide Transition Services for a period of up to six (6) months from the effective date of termination; provided that CytoDyn will have the ability to terminate Transition Services on a service-by-service basis as they are transitioned; and (iv) Transition Services will be reimbursed at Vyera's actual cost plus ten percent (10%) by CytoDyn. (v) At CytoDyn's reasonable request and subject to the terms of the applicable agreement, Vyera will use its reasonable best efforts to assign to CytoDyn any Third Party agreements that relate to the Transition Services matters solely for Licensed Product in the Territory in the Field.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Audit Rights_1",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable prior notice, but not more than once per Calendar Year, such records of Vyera and its Affiliates shall be available during Vyera's and its Affiliates regular business hours for a period of three (3) years from the end of the Calendar Year to which they pertain for examination at the expense of CytoDyn by an independent certified public accountant selected by CytoDyn and reasonably acceptable to Vyera, for the sole purpose of verifying the accuracy of the financial reports and correctness of the payments furnished by Vyera pursuant to this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Audit Rights_0",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "To the extent permitted under Applicable Law and, if applicable, its relevant Third Party agreements, (a) CytoDyn shall provide Vyera with reasonable advance notice of any scheduled regulatory inspection of CytoDyn or Third Party Manufacturing facilities used for supply of the Licensed Product as contemplated by Article 6, and (b) Vyera shall be allowed to participate in any pre-approval readiness activities and audits for CytoDyn or its Third Party Manufacturing facilities.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Uncapped Liability_0",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "EXCEPT FOR A PARTY'S OBLIGATIONS SET FORTH IN THIS ARTICLE 13, AND ANY BREACH OF ARTICLE 10 (CONFIDENTIALITY), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY'S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST ROYALTIES, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Cap On Liability_0",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "EXCEPT FOR A PARTY'S OBLIGATIONS SET FORTH IN THIS ARTICLE 13, AND ANY BREACH OF ARTICLE 10 (CONFIDENTIALITY), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY'S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST ROYALTIES, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Cap On Liability_0",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "FOR CLARITY AND NOTWITHSTANDING THE PROVISIONS OF THE FIRST SENTENCE OF THIS SECTION 13.5, ROYALTIES AND MILESTONES PAYABLE TO CYTODYN IN CONNECTION WITH VYERA'S COMMERCIALIZATION OF LICENSED PRODUCTS IN ACCORDANCE WITH THE TERMS OF THIS AGREEMENT COULD CONSTITUTE DIRECT DAMAGES TO THE EXTENT AWARDED IN ACCORDANCE WITH ARTICLE 12.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Insurance_1",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon reques",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Insurance_1",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall provide the other Party with prompt written notice of any cancellation, non-renewal or material change in such insurance that could materially adversely affect the rights of the other Party hereunder, and shall provide such notice within thirty (30) days after any such cancellation, non-renewal or material change.",
      "page_number": 1,
      "words": [
        {
          "text": "1.8 \"API\"' means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process (i.e., any substance.",
          "bbox": [
            275.0,
            294.0,
            2895.0,
            334.0
          ],
          "confidence": 0.9898456931114197
        },
        {
          "text": "intended to be used in the manufacture of a drug product and that is intended to furnish pharmacological activity in the cure, treatment or prevention of",
          "bbox": [
            276.0,
            349.0,
            3023.0,
            391.0
          ],
          "confidence": 0.9942246079444885
        },
        {
          "text": "disease).",
          "bbox": [
            273.0,
            400.0,
            439.0,
            448.0
          ],
          "confidence": 0.9966335296630859
        },
        {
          "text": "1.9 \"Applicable Law\"' means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,",
          "bbox": [
            277.0,
            510.0,
            2951.0,
            556.0
          ],
          "confidence": 0.9897712469100952
        },
        {
          "text": "including, without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. s335a et seq.), U.S. Patent",
          "bbox": [
            277.0,
            566.0,
            3056.0,
            609.0
          ],
          "confidence": 0.9836246967315674
        },
        {
          "text": "Act (35 U.S.C. $1 et seq.), Federal Civil False Claims Act (31 U.S.C. $3729 et seq.), and Anti-Kickback Statute (42 U.S.C. $1320a-7b et seq.), all as amended.",
          "bbox": [
            279.0,
            621.0,
            3045.0,
            663.0
          ],
          "confidence": 0.9761050939559937
        },
        {
          "text": "from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder..",
          "bbox": [
            275.0,
            674.0,
            2173.0,
            718.0
          ],
          "confidence": 0.9929153323173523
        },
        {
          "text": "1.10 \"Arbitration Request' has the meaning set forth in Section 12.3(b).",
          "bbox": [
            277.0,
            784.0,
            1580.0,
            826.0
          ],
          "confidence": 0.9800654649734497
        },
        {
          "text": "1.11 \"Bankruptcy Laws\" has the meaning set forth in Section 11.6(b)..",
          "bbox": [
            279.0,
            894.0,
            1530.0,
            936.0
          ],
          "confidence": 0.976145327091217
        },
        {
          "text": "1.12 \"Biosimilar Competitor\" means, with respect to the Licensed Product, a drug or biological product that has been determined by the FDA to be",
          "bbox": [
            275.0,
            1000.0,
            2953.0,
            1043.0
          ],
          "confidence": 0.997501790523529
        },
        {
          "text": "therapeutically equivalent to the Licensed Product, such that it may be substituted by a pharmacist for the Licensed Product in the Field in the Territory",
          "bbox": [
            279.0,
            1056.0,
            3012.0,
            1100.0
          ],
          "confidence": 0.9942712187767029
        },
        {
          "text": "without the need for such pharmacist to seek authorization from the physician that prescribed the Licensed Product.",
          "bbox": [
            279.0,
            1115.0,
            2374.0,
            1151.0
          ],
          "confidence": 0.9970287084579468
        },
        {
          "text": "1.13 \"Biosimilar Entry Date\" means the first day of the first Calendar Quarter that occurs after Biosimilar Competitor(s) have achieved at least [***] in",
          "bbox": [
            275.0,
            1217.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9931293725967407
        },
        {
          "text": "the Field in the Territory..",
          "bbox": [
            275.0,
            1272.0,
            714.0,
            1318.0
          ],
          "confidence": 0.9842923879623413
        },
        {
          "text": "1.14 \"BLA\" means a Biologics License Application (as defined in the FDCA), including all supplements, amendments, variations, extensions and.",
          "bbox": [
            275.0,
            1380.0,
            2900.0,
            1427.0
          ],
          "confidence": 0.989626944065094
        },
        {
          "text": "renewals thereof.",
          "bbox": [
            275.0,
            1440.0,
            585.0,
            1476.0
          ],
          "confidence": 0.9998825192451477
        },
        {
          "text": "1.15 \"Breaching Party\" has the meaning set forth in Section 11.4",
          "bbox": [
            277.0,
            1546.0,
            1464.0,
            1590.0
          ],
          "confidence": 0.9876763820648193
        },
        {
          "text": "1.16 \"Business Day\"' means a day other than Saturday, Sunday or any other day on which commercial banks located in the State of New York or the State.",
          "bbox": [
            277.0,
            1654.0,
            3050.0,
            1698.0
          ],
          "confidence": 0.9902433156967163
        },
        {
          "text": "of Washington, U.S., are authorized or obligated by Applicable Law to close..",
          "bbox": [
            275.0,
            1709.0,
            1662.0,
            1754.0
          ],
          "confidence": 0.9855461716651917
        },
        {
          "text": "1.17 \"Calendar Quarter\" means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and.",
          "bbox": [
            275.0,
            1816.0,
            2902.0,
            1862.0
          ],
          "confidence": 0.9902397990226746
        },
        {
          "text": "December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete",
          "bbox": [
            277.0,
            1875.0,
            2914.0,
            1917.0
          ],
          "confidence": 0.9878926277160645
        },
        {
          "text": "Calendar Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            275.0,
            1926.0,
            2739.0,
            1970.0
          ],
          "confidence": 0.9902106523513794
        },
        {
          "text": "1.18 \"Calendar Year\"' means the twelve-month period ending on December 31; provided, however, that (a) the first Calendar Year of the Term shall begin",
          "bbox": [
            277.0,
            2036.0,
            3027.0,
            2080.0
          ],
          "confidence": 0.9932020306587219
        },
        {
          "text": "on the Effective Date and end on December 31, 2019; and (b) the last Calendar Year of the Term shall end on the effective date of expiration or termination",
          "bbox": [
            277.0,
            2092.0,
            3036.0,
            2129.0
          ],
          "confidence": 0.9955219626426697
        },
        {
          "text": "of this Agreement..",
          "bbox": [
            277.0,
            2149.0,
            613.0,
            2187.0
          ],
          "confidence": 0.9688924551010132
        },
        {
          "text": "1.19 \"Change of Control'' means, with respect to Vyera, (a) the sale of all or substantially all of its assets; (b) any merger, consolidation or acquisition of.",
          "bbox": [
            277.0,
            2253.0,
            3025.0,
            2295.0
          ],
          "confidence": 0.9914369583129883
        },
        {
          "text": "Vyera, by or into another Person; and/or (c) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct.",
          "bbox": [
            281.0,
            2312.0,
            3036.0,
            2354.0
          ],
          "confidence": 0.9935190081596375
        },
        {
          "text": "or indirect parent entities, other than: (i) transactions involving solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand.",
          "bbox": [
            277.0,
            2368.0,
            3038.0,
            2405.0
          ],
          "confidence": 0.9900050163269043
        },
        {
          "text": "and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of Vyera (or an",
          "bbox": [
            277.0,
            2423.0,
            3029.0,
            2460.0
          ],
          "confidence": 0.9990707635879517
        },
        {
          "text": "Affiliate, as applicable) immediately prior to such transaction hold at least fifty percent (50%) of the voting power of the surviving company or ultimate",
          "bbox": [
            281.0,
            2474.0,
            2998.0,
            2516.0
          ],
          "confidence": 0.9895808100700378
        },
        {
          "text": "parent company of the surviving company; in each of clauses (a)-(c), in one or more related transactions..",
          "bbox": [
            275.0,
            2525.0,
            2170.0,
            2573.0
          ],
          "confidence": 0.9926127791404724
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9836369752883911
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Insurance_0",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party, at its own expense, shall maintain comprehensive general liability, product liability and other appropriate insurance for the activities such Party undertakes pursuant to this Agreement, from reputable and financially secure insurance carriers in a form and at levels consistent with sound business practice and adequate in light of its obligations under this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Covenant Not To Sue_0",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterpartyâs ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "CytoDyn shall have the right to terminate this Agreement in its entirety upon written notice to Vyera on the occurrence of any of the following: (a) Vyera or any of its Affiliates directly or indirectly, challenges, disputes, or assists any Third Party to dispute or challenge, in a legal or administrative proceeding the patentability, enforceability or validity of any CytoDyn Patents;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.5",
          "bbox": [
            2835.0,
            283.0,
            3058.0,
            322.0
          ],
          "confidence": 0.9776037335395813
        },
        {
          "text": "Certain identified information has been excluded because it is both not material and would",
          "bbox": [
            843.0,
            391.0,
            2489.0,
            431.0
          ],
          "confidence": 0.9986586570739746
        },
        {
          "text": "likely cause competitive harm if publicly disclosed.",
          "bbox": [
            1198.0,
            448.0,
            2135.0,
            490.0
          ],
          "confidence": 0.9939900636672974
        },
        {
          "text": "COMMIERCIALIZATION AND LICENSE AGREEMENT",
          "bbox": [
            1156.0,
            532.0,
            2177.0,
            563.0
          ],
          "confidence": 0.9826664924621582
        },
        {
          "text": "This Commercialization and License Agreement (this \"Agreement') is made effective as of December 17, 2019 (the \"Effective Date') by and between",
          "bbox": [
            277.0,
            638.0,
            2954.0,
            680.0
          ],
          "confidence": 0.9907844662666321
        },
        {
          "text": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\"Vyera\"), and CytoDyn Inc., a Delaware corporation (\"CytoDyn\"). CytoDyn and Vyera",
          "bbox": [
            281.0,
            694.0,
            3021.0,
            736.0
          ],
          "confidence": 0.985166072845459
        },
        {
          "text": "are sometimes referred to herein individually as a \"Party\"' and collectively as the \"Parties.\"",
          "bbox": [
            274.0,
            744.0,
            1925.0,
            789.0
          ],
          "confidence": 0.9787416458129883
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            910.0,
            1774.0,
            947.0
          ],
          "confidence": 0.9995864629745483
        },
        {
          "text": "WHEREAS, Vyera is a pharmaceutical company engaged in the commercialization of products useful in the amelioration, treatment or prevention of",
          "bbox": [
            279.0,
            1020.0,
            2936.0,
            1062.0
          ],
          "confidence": 0.9919267892837524
        },
        {
          "text": "certain human diseases and conditions.",
          "bbox": [
            275.0,
            1073.0,
            991.0,
            1117.0
          ],
          "confidence": 0.9887217283248901
        },
        {
          "text": "WHEREAS, CytoDyn has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its",
          "bbox": [
            279.0,
            1182.0,
            3040.0,
            1224.0
          ],
          "confidence": 0.9937103986740112
        },
        {
          "text": "PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (\"HIv\") infection, as well as related HIV infection",
          "bbox": [
            276.0,
            1237.0,
            2922.0,
            1279.0
          ],
          "confidence": 0.9911673665046692
        },
        {
          "text": "indications.",
          "bbox": [
            277.0,
            1294.0,
            488.0,
            1332.0
          ],
          "confidence": 0.9998663067817688
        },
        {
          "text": "WHEREAS, the Parties desire that, upon regulatory approval of PRO 140 for the Initial Indication (as defined below), Vyera will Commercialize (as defined",
          "bbox": [
            279.0,
            1400.0,
            3043.0,
            1444.0
          ],
          "confidence": 0.9904739260673523
        },
        {
          "text": "below) Licensed Products (as defined below) in the Field (as defined below) in the Territory (as defined below), all in accordance with the terms and",
          "bbox": [
            277.0,
            1453.0,
            2936.0,
            1497.0
          ],
          "confidence": 0.9896926283836365
        },
        {
          "text": "conditions of this Agreement.",
          "bbox": [
            279.0,
            1513.0,
            816.0,
            1550.0
          ],
          "confidence": 0.9999642372131348
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:",
          "bbox": [
            276.0,
            1619.0,
            2675.0,
            1661.0
          ],
          "confidence": 0.9925454258918762
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1559.0,
            1778.0,
            1776.0,
            1820.0
          ],
          "confidence": 0.9973465800285339
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1836.0,
            1803.0,
            1873.0
          ],
          "confidence": 0.9992309212684631
        },
        {
          "text": "1.1 \"AAA\" has the meaning set forth in Section 12.3(a).",
          "bbox": [
            279.0,
            1944.0,
            1274.0,
            1985.0
          ],
          "confidence": 0.9885876178741455
        },
        {
          "text": "1.2 \"AAI Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2054.0,
            1457.0,
            2096.0
          ],
          "confidence": 0.9794711470603943
        },
        {
          "text": "1.3 \"Affiliate' means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party. For the",
          "bbox": [
            277.0,
            2164.0,
            2933.0,
            2206.0
          ],
          "confidence": 0.9898219108581543
        },
        {
          "text": "purposes of this definition, the word \"control\" (including, with correlative meaning, the terms \"controlled by' or \"under the common control with')",
          "bbox": [
            275.0,
            2215.0,
            2933.0,
            2262.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies",
          "bbox": [
            276.0,
            2273.0,
            3049.0,
            2315.0
          ],
          "confidence": 0.9942028522491455
        },
        {
          "text": "of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise.",
          "bbox": [
            277.0,
            2328.0,
            2644.0,
            2370.0
          ],
          "confidence": 0.99436354637146
        },
        {
          "text": "1.4 \"AGC Agreement' has the meaning set forth in Section 9.2(o)",
          "bbox": [
            277.0,
            2436.0,
            1474.0,
            2478.0
          ],
          "confidence": 0.9864988327026367
        },
        {
          "text": "1.5 \"Agreement' has the meaning set forth in the introductory paragraph",
          "bbox": [
            275.0,
            2542.0,
            1611.0,
            2588.0
          ],
          "confidence": 0.9908771514892578
        },
        {
          "text": "1.6 \"Alliance Manager\"' means, with respect to each Party, the person appointed by such Party from within its organization to coordinate and facilitate",
          "bbox": [
            277.0,
            2653.0,
            2998.0,
            2695.0
          ],
          "confidence": 0.9856281280517578
        },
        {
          "text": "the communication, interaction and cooperation of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between",
          "bbox": [
            275.0,
            2706.0,
            3041.0,
            2752.0
          ],
          "confidence": 0.9930182099342346
        },
        {
          "text": "the Parties with respect to the activities conducted pursuant to this Agreement.",
          "bbox": [
            277.0,
            2763.0,
            1713.0,
            2803.0
          ],
          "confidence": 0.9983898401260376
        },
        {
          "text": "1.7 \"Annual WAC\" means the annual wholesale acquisition cost for the Licensed Product.",
          "bbox": [
            277.0,
            2871.0,
            1912.0,
            2913.0
          ],
          "confidence": 0.9951673150062561
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9845162630081177
        }
      ]
    },
    {
      "id": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement__Covenant Not To Sue_2",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterpartyâs ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Neither Vyera, nor any of its Affiliates shall directly or indirectly, challenge, or assist any Third Party to dispute or challenge, in a legal or administrative proceeding the patentability, enforceability or validity of any CytoDyn Patents.",
      "page_number": 2,
      "words": [
        {
          "text": "1.20 \"Claim\" has the meaning set forth in Section 13.1..",
          "bbox": [
            277.0,
            292.0,
            1271.0,
            333.0
          ],
          "confidence": 0.9812736511230469
        },
        {
          "text": "1.21 \"Clinical Trial' means any human clinical study or trial of a Licensed Product in the Field in the Territory..",
          "bbox": [
            275.0,
            398.0,
            2275.0,
            446.0
          ],
          "confidence": 0.987525463104248
        },
        {
          "text": "1.22 \"Combination Product\"' means a product that is Commercialized by Vyera and/or its Affiliates under this Agreement and that comprises, consists of,",
          "bbox": [
            275.0,
            510.0,
            3040.0,
            554.0
          ],
          "confidence": 0.9895656108856201
        },
        {
          "text": "or incorporates two or more APIs (whether administered together or separately), which includes leronlimab as one of the APIs together with one or more",
          "bbox": [
            277.0,
            566.0,
            3030.0,
            610.0
          ],
          "confidence": 0.9959484934806824
        },
        {
          "text": "additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the formulation or mode of administration of such",
          "bbox": [
            276.0,
            621.0,
            2929.0,
            663.0
          ],
          "confidence": 0.9954297542572021
        },
        {
          "text": "Combination Product. For the sake of clarity, a Combination Product is a Licensed Product.",
          "bbox": [
            279.0,
            678.0,
            1912.0,
            714.0
          ],
          "confidence": 0.9996550679206848
        },
        {
          "text": "1.23 \"Commercial Failure' means that Vyera fails to achieve aggregate [***].",
          "bbox": [
            274.0,
            778.0,
            1691.0,
            830.0
          ],
          "confidence": 0.9877095222473145
        },
        {
          "text": "1.24 \"Commercialization' means any and all pre-launch, launch and post-launch activities related to the marketing, promoting, distributing (to Third",
          "bbox": [
            279.0,
            894.0,
            2971.0,
            936.0
          ],
          "confidence": 0.9911439418792725
        },
        {
          "text": "Parties), offering for sale and selling a Licensed Product in the Field in the Territory. For clarity, Commercialization does not include Development and/or",
          "bbox": [
            277.0,
            948.0,
            3016.0,
            990.0
          ],
          "confidence": 0.9954667687416077
        },
        {
          "text": "Manufacturing of a Licensed Product. When used as a verb, \"Commercialize\" means to engage in Commercialization..",
          "bbox": [
            277.0,
            1003.0,
            2411.0,
            1045.0
          ],
          "confidence": 0.9929887652397156
        },
        {
          "text": "1.25 \"Commercialization Plan\"' has the meaning set forth in Section 5.2.",
          "bbox": [
            277.0,
            1109.0,
            1584.0,
            1151.0
          ],
          "confidence": 0.9814334511756897
        },
        {
          "text": "1.26 \"Commercially Reasonable Efforts\"' means: (a) with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its",
          "bbox": [
            279.0,
            1222.0,
            2944.0,
            1259.0
          ],
          "confidence": 0.989510178565979
        },
        {
          "text": "Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective,",
          "bbox": [
            279.0,
            1274.0,
            2933.0,
            1316.0
          ],
          "confidence": 0.9922087788581848
        },
        {
          "text": "activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances; and (b) with",
          "bbox": [
            279.0,
            1332.0,
            2956.0,
            1369.0
          ],
          "confidence": 0.9923081398010254
        },
        {
          "text": "respect to Development and Commercialization of any Licensed Product for any indication by a Party, efforts and resources consistent with those efforts",
          "bbox": [
            274.0,
            1381.0,
            3036.0,
            1427.0
          ],
          "confidence": 0.9998706579208374
        },
        {
          "text": "and resources commonly used by a similarly situated biotechnology company with respect to a product owned by it or to which it has similar rights,",
          "bbox": [
            276.0,
            1438.0,
            2947.0,
            1480.0
          ],
          "confidence": 0.9859208464622498
        },
        {
          "text": "which product is at a similar stage in its development or product life and is of similar market potential taking into account (i) the patent and other",
          "bbox": [
            279.0,
            1493.0,
            2882.0,
            1535.0
          ],
          "confidence": 0.988565981388092
        },
        {
          "text": "proprietary position of the Licensed Product and (ii) the anticipated profitability of the Licensed Product..",
          "bbox": [
            277.0,
            1544.0,
            2171.0,
            1592.0
          ],
          "confidence": 0.9909676313400269
        },
        {
          "text": "1.27 \"Competitive Product' means any product for the treatment or prevention of [***], leronlimab that is not a Licensed Product..",
          "bbox": [
            277.0,
            1656.0,
            2628.0,
            1698.0
          ],
          "confidence": 0.9867275357246399
        },
        {
          "text": "1.28 \"Confidential Information\"' means, subject to Article 10, all non-public or proprietary information not otherwise included in Know-How disclosed by.",
          "bbox": [
            277.0,
            1765.0,
            3049.0,
            1807.0
          ],
          "confidence": 0.9923374652862549
        },
        {
          "text": "either Party to the other Party in connection with the activities contemplated by this Agreement, which may include ideas, inventions, discoveries,",
          "bbox": [
            277.0,
            1820.0,
            2918.0,
            1862.0
          ],
          "confidence": 0.9925811290740967
        },
        {
          "text": "concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets,.",
          "bbox": [
            277.0,
            1877.0,
            2846.0,
            1913.0
          ],
          "confidence": 0.9897582530975342
        },
        {
          "text": "technology, inventories, machines, techniques, development, designs, drawings, computer programs, knowledge, skill, experience, documents, apparatus,",
          "bbox": [
            274.0,
            1926.0,
            3047.0,
            1974.0
          ],
          "confidence": 0.9925311803817749
        },
        {
          "text": "results, clinical and regulatory strategies, Regulatory Documentation, and submissions pertaining to, or made in association with, filings with any",
          "bbox": [
            274.0,
            1981.0,
            2902.0,
            2027.0
          ],
          "confidence": 0.9985519647598267
        },
        {
          "text": "Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and",
          "bbox": [
            279.0,
            2039.0,
            2949.0,
            2076.0
          ],
          "confidence": 0.9960005879402161
        },
        {
          "text": "descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product",
          "bbox": [
            279.0,
            2096.0,
            2991.0,
            2133.0
          ],
          "confidence": 0.9948955178260803
        },
        {
          "text": "samples and other samples, physical, chemical and biological materials and compounds and information related to such materials and compounds, and",
          "bbox": [
            277.0,
            2147.0,
            2991.0,
            2189.0
          ],
          "confidence": 0.9983083009719849
        },
        {
          "text": "any modifications, improvements, designs, and recipes without regard as to whether any of the foregoing is marked \"confidential' or \"proprietary,\" or",
          "bbox": [
            277.0,
            2202.0,
            2982.0,
            2246.0
          ],
          "confidence": 0.9895987510681152
        },
        {
          "text": "disclosed in oral, written, graphic, or electronic form. Confidential Information shall include the terms and conditions of this Agreement..",
          "bbox": [
            275.0,
            2253.0,
            2722.0,
            2299.0
          ],
          "confidence": 0.998028039932251
        },
        {
          "text": "Source: CYTODYN INC., 10-Q, 1/9/2020",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9870999455451965
        }
      ]
    }
  ],
  "failed_annotations": []
}